Estradiol acetate

Estradiol acetate

Clinical data
Pronunciation	/ˌɛstrəˈdaɪoʊl ˈæsəteɪt/ ES-trə-DYE-ohl ASS-ə-tayt
Trade names	Femtrace, Femring, Menoring
Routes of administration	Oral, vaginal (ring)
ATC code	G03CA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate
CAS Number	4245-41-4
PubChem CID	9818306
DrugBank	DBSALT000065
ChemSpider	7994056
UNII	5R97F5H93P
KEGG	D04061
ChEMBL	CHEMBL1200430
ECHA InfoCard	100.110.039
Chemical and physical data
Formula	C20H26O3
Molar mass	314.419 g/mol
3D model (Jmol)	Interactive image
SMILES C(C)(=O)Oc1ccc2[C@@H]3CC[C@@]4([C@H](CC[C@@H]4[C@@H]3CCc2c1)O)C
InChI InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1 Key:FHXBMXJMKMWVRG-SLHNCBLASA-N

Estradiol acetate (INN, USAN, BAN) (brand names Femtrace, Femring, Menoring), or estradiol 3-acetate, is a semisynthetic, steroidal estrogen and an estrogen ester – specifically, the 3-acetate ester of estradiol. It acts as a prodrug of estradiol, and hence, is considered to be a natural, bioidentical form of estrogen. Estradiol acetate is relatively recent to the market, having been first approved in a vaginal ring formulation as Menoring in the United Kingdom in 2001, followed by another vaginal ring formulation as Femring in the United States in 2003, and finally as an oral preparation as Femtrace in the United States in 2004. It is used as a component of hormone replacement therapy to treat and prevent symptoms of menopause such as osteoporosis in postmenopausal women.

The Women's Health Initiative studies report increased health risks for postmenopausal women when using unopposed estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.